Avita FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini. As a line extension of the RECELL GO system, the RECELL GO mini disposable cartridge is designed specifically to treat smaller wounds up to 480 square centimeters, compared to the standard RECELL GO disposable cartridge, which treats an area of 1,920 square centimeters.

https://www.globenewswire.com/news-release/2024/12/23/3001481/0/en/AVITA-Medical-Announces-FDA-Approval-of-RECELL-GO-mini-Optimizing-Treatment-for-Smaller-Wounds.html